AU2020404453B2 - CXCL10 binding proteins and uses thereof - Google Patents

CXCL10 binding proteins and uses thereof Download PDF

Info

Publication number
AU2020404453B2
AU2020404453B2 AU2020404453A AU2020404453A AU2020404453B2 AU 2020404453 B2 AU2020404453 B2 AU 2020404453B2 AU 2020404453 A AU2020404453 A AU 2020404453A AU 2020404453 A AU2020404453 A AU 2020404453A AU 2020404453 B2 AU2020404453 B2 AU 2020404453B2
Authority
AU
Australia
Prior art keywords
cxcl10
subject
seq
antibody
cxcl1o
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020404453A
Other languages
English (en)
Other versions
AU2020404453A1 (en
Inventor
Sung-Woog Kang
Adam Rainczuk
Andrew N. STEPHENS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hudson Institute of Medical Research
Original Assignee
Hudson Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904859A external-priority patent/AU2019904859A0/en
Application filed by Hudson Institute of Medical Research filed Critical Hudson Institute of Medical Research
Publication of AU2020404453A1 publication Critical patent/AU2020404453A1/en
Application granted granted Critical
Publication of AU2020404453B2 publication Critical patent/AU2020404453B2/en
Priority to AU2023201412A priority Critical patent/AU2023201412A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4715—Cytokine-induced proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2020404453A 2019-12-20 2020-12-18 CXCL10 binding proteins and uses thereof Active AU2020404453B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023201412A AU2023201412A1 (en) 2019-12-20 2023-03-07 CXCL10 binding proteins and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019904859A AU2019904859A0 (en) 2019-12-20 CXCL10 binding proteins and uses thereof
AU2019904859 2019-12-20
PCT/AU2020/051403 WO2021119761A1 (en) 2019-12-20 2020-12-18 Cxcl10 binding proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023201412A Division AU2023201412A1 (en) 2019-12-20 2023-03-07 CXCL10 binding proteins and uses thereof

Publications (2)

Publication Number Publication Date
AU2020404453A1 AU2020404453A1 (en) 2022-07-07
AU2020404453B2 true AU2020404453B2 (en) 2022-12-08

Family

ID=76476918

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020404453A Active AU2020404453B2 (en) 2019-12-20 2020-12-18 CXCL10 binding proteins and uses thereof
AU2023201412A Abandoned AU2023201412A1 (en) 2019-12-20 2023-03-07 CXCL10 binding proteins and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023201412A Abandoned AU2023201412A1 (en) 2019-12-20 2023-03-07 CXCL10 binding proteins and uses thereof

Country Status (8)

Country Link
US (2) US11725048B2 (enExample)
EP (1) EP4077385A4 (enExample)
JP (1) JP7807372B2 (enExample)
KR (1) KR20220117317A (enExample)
CN (1) CN115397851B (enExample)
AU (2) AU2020404453B2 (enExample)
IL (1) IL294045A (enExample)
WO (1) WO2021119761A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114369171B (zh) * 2022-01-27 2023-04-21 重庆睿仕康生物医药有限公司 一种融合CXCR3和αFR抗体的嵌合抗原受体及其效应细胞和在治疗卵巢癌中的应用
WO2025076597A1 (en) * 2023-10-11 2025-04-17 Cleo Diagnostics Ltd Methods of detecting and/or diagnosing a malignant condition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100040577A1 (en) * 2006-09-14 2010-02-18 Institut Pasteur METHODS OF USING sIP-10, CD26 INHIBITORS AND CXCR3 LEVELS IN A SAMPLE TO ASSESS CLEARANCE OF INFECTION, RESPONSE TO INTERFERON THERAPY, AND TREATING CHRONIC INFECTIONS

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4978503A (en) 1984-06-13 1990-12-18 Ares-Serono Research & Development Limited Partnership Devices for use in chemical test procedures
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5356817A (en) 1988-06-09 1994-10-18 Yale University Methods for detecting the onset, progression and regression of gynecologic cancers
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2063348T3 (es) 1989-04-11 1995-01-01 Ars Holding 89 Nv Vehiculo de ensayo multianalitico.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU3691093A (en) 1992-04-14 1993-10-21 Hybritech Incorporated Methods of inhibiting the growth of multidrug resistant tumors
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
CA2145278C (en) 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ATE370961T1 (de) 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
US6562622B1 (en) 1998-05-08 2003-05-13 Diatech Pty, Ltd Continuous in vitro evolution
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP4369662B2 (ja) 2001-04-26 2009-11-25 アビディア インコーポレイテッド 単量体ドメインのコンビナトリアルライブラリー
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US7964194B2 (en) 2002-11-15 2011-06-21 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
US8563476B2 (en) 2002-11-15 2013-10-22 Morehouse School Of Medicine Anti-CXCL9, anti-CXCL10, anti-CXCL11, anti-CXCL13, anti-CXCR3 and anti-CXCR5 agents for inflammatory disorders
US20120135415A1 (en) 2002-11-15 2012-05-31 Morehouse School Of Medicine Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies
AU2004245038A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-CD3 antibody
CA2531238C (en) 2003-07-04 2015-02-24 Affibody Ab Polypeptides having binding affinity for her2
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
JP4958555B2 (ja) 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトＩｇＧ４抗体
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
WO2007019620A1 (en) 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
NZ544432A (en) 2005-12-23 2009-07-31 Pacific Edge Biotechnology Ltd Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS
AU2007350900A1 (en) 2007-04-05 2008-10-16 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of ovarian cancer
CN101971033A (zh) 2007-06-04 2011-02-09 戴诺普雷克斯公司 用于结直肠癌的生物标志物组合
GB0806812D0 (en) * 2008-04-15 2008-05-14 Univ Leuven Kath Citrullinated cytokines
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
EP2367000A1 (en) 2010-03-04 2011-09-21 Charité Universitätsmedizin Berlin High throughput analysis of T-cell receptor repertoires
US9617329B2 (en) 2010-10-01 2017-04-11 Csl Limited Method of cloning nucleic acid
JP2014505239A (ja) 2010-12-14 2014-02-27 モアハウス スクール オブ メディスン 癌の治療または検出のための抗ｃｘｃｌ１３および抗ｃｘｃｒ５抗体の使用
CN103582815A (zh) * 2011-02-24 2014-02-12 佛米利昂公司 用于卵巢癌的生物标志物组、诊断方法和测试试剂盒
US10308980B2 (en) 2011-11-04 2019-06-04 Oslo Universitetssykehus Hf Methods and biomarkers for analysis of colorectal cancer
KR101452865B1 (ko) 2012-09-17 2014-10-21 서울대학교산학협력단 신규한 ｉｐ－１０ 에피토프 및 이에 대한 항체
DK2914739T3 (da) 2012-11-05 2017-11-27 Novigenix Sa Kombinationer af biomarkører for kolorektale tumorer
EP3060250A1 (en) * 2013-10-22 2016-08-31 NovImmune SA Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers
EP3073268A1 (en) 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
US10556948B2 (en) 2015-11-30 2020-02-11 Bristol-Myers Squibb Company IP-10 antibodies and their uses
CN106868012B (zh) * 2015-12-14 2020-08-18 广西医科大学 靶向肿瘤血管内皮细胞的ip10单链抗体及制备方法
WO2020109570A1 (en) 2018-11-30 2020-06-04 Gbg Forschungs Gmbh Method for predicting the response to cancer immunotherapy in cancer patients
WO2020124083A1 (en) 2018-12-14 2020-06-18 The Brigham And Women's Hospital, Inc. Biomarker panels for on-treatment prediction of response to immuno-oncology drugs
US20220381791A1 (en) 2019-10-01 2022-12-01 bioMérieux Method for determining an individual ability to respond to a stimulus
US20210347847A1 (en) 2020-05-11 2021-11-11 The Broad Institute, Inc. Therapeutic targeting of malignant cells using tumor markers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100040577A1 (en) * 2006-09-14 2010-02-18 Institut Pasteur METHODS OF USING sIP-10, CD26 INHIBITORS AND CXCR3 LEVELS IN A SAMPLE TO ASSESS CLEARANCE OF INFECTION, RESPONSE TO INTERFERON THERAPY, AND TREATING CHRONIC INFECTIONS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CASROUGE, A. ET AL.: "Discrimination of agonist and antagonist forms of CXCL10 in biological samples", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 167, 2011, pages 137 - 148 *
LOOS, T. ET AL. BLOOD., vol. 112, no. 7, 2008, pages 2648 - 2656 *
RAINCZUK ADAM, RAO JYOTHSNA R., GATHERCOLE JESSICA L., FAIRWEATHER NICOLE J., CHU SIMON, MASADAH RINA, JOBLING THOMAS W., DEB-CHOU: "Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours : Antagonistic CXCL10 in Ovarian Tumours", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC., US, vol. 134, no. 3, 1 February 2014 (2014-02-01), US , pages 530 - 541, XP055837412, ISSN: 0020-7136, DOI: 10.1002/ijc.28393 *

Also Published As

Publication number Publication date
US20240076366A1 (en) 2024-03-07
US11725048B2 (en) 2023-08-15
JP7807372B2 (ja) 2026-01-27
KR20220117317A (ko) 2022-08-23
US12384838B2 (en) 2025-08-12
US20230051580A1 (en) 2023-02-16
IL294045A (en) 2022-08-01
AU2020404453A1 (en) 2022-07-07
EP4077385A1 (en) 2022-10-26
CN115397851A (zh) 2022-11-25
CN115397851B (zh) 2025-12-12
EP4077385A4 (en) 2023-12-13
WO2021119761A1 (en) 2021-06-24
AU2023201412A1 (en) 2023-04-13
JP2023508023A (ja) 2023-02-28

Similar Documents

Publication Publication Date Title
JP5409628B2 (ja) 抗ｔｗｅａｋ受容体抗体の治療上の使用
US11119096B2 (en) Universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug-antibodies in samples
US9212221B2 (en) Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
US12384838B2 (en) CXCL10 binding proteins and uses thereof
US11543416B2 (en) Method for quantifying therapeutic antibodies
US11053303B2 (en) Antibody-like peptides for quantifying therapeutic antibodies
TW201207396A (en) Novel antibody for the diagnosis and/or prognosis of cancer
JP2023537131A5 (enExample)
WO2025076597A1 (en) Methods of detecting and/or diagnosing a malignant condition
JP7023942B2 (ja) 卵巣癌バイオマーカーおよびその使用
WO2022078490A1 (zh) 抗erbb3抗体或其抗原结合片段及其医药用途
US20240174741A1 (en) Il-38-specific antibodies
WO2025227208A1 (en) Anti-npy-y1 antibodies and uses thereof
JP2022501062A (ja) Ｅｐｎ１を標的とする抗体
HK40036076A (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof
EP3371592A1 (en) A method for quantifying therapeutic antibodies
HK40011229B (en) Ovarian cancer biomarker and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)